Metropolis Healthcare Limited has announced that its wholly owned subsidiary, Metropolis Histoxpert Digital Services Private Limited, has entered into a definitive agreement to acquire the Dehradun-based Dr Ahujas’ Pathology and Imaging Centre (DAPIC), a prominent diagnostics chain in Uttarakhand.
Established in 1990 by Dr. Alok Ahuja and Dr. Alka Ahuja, DAPIC has built a strong reputation for quality and reliability in diagnostics. The chain operates two NABL- and NABH-accredited laboratories, 11 patient service centres, and nine hospital-based diagnostic centres across the state. It offers a wide range of pathology and soft radiology services, including ultrasound, ECG, and X-ray.
For FY 2024-25, DAPIC posted an estimated unaudited revenue of ₹11.5 crore, with pathology contributing 73% and radiology 27% to the topline. Notably, 80% of its business comes from walk-in patients, reinforcing its strong B2C presence. This acquisition will allow Metropolis to further strengthen its footprint in North India, especially in the high-potential Uttarakhand market.
The company stated that this all-cash transaction is valued at ₹35.01 crore, with Metropolis Histoxpert acquiring 100% ownership in DAPIC. As part of the agreement, the founders, Dr Alok Ahuja and Dr Alka Ahuja, will continue their involvement with the business to ensure operational continuity and a smooth transition.
EY served as the exclusive financial advisor to DAPIC, while BDO India LLP advised Metropolis Healthcare Limited.
Speaking on the acquisition, Ms Ameera Shah, Promoter and Executive Chairperson, Metropolis Healthcare Limited, said, “Dr Ahujas’ Pathology & Imaging Centre has established a strong reputation for high-quality B2C services, scientific excellence, and patient trust, making it an ideal addition to Metropolis’ growth strategy. Together with the acquisition of Core Diagnostics, a leader in oncology testing, Scientific Pathology, the dominant chain in Agra, and now DAPIC, the leading diagnostic chain in Dehradun, we are further strengthening our ‘String of Pearls’ strategy—aimed at building a robust and regionally diverse diagnostic network across North India.”
He further added, “These strategic moves have expanded the North India contribution to our overall revenues from 8% to an estimated 14–15%. Building on this momentum, we aim to accelerate our expansion across Uttar Pradesh and Uttarakhand—two high-growth markets with significant potential. We are delighted to welcome Dr. Alok Ahuja and Dr. Alka Ahuja into the Metropolis family as we integrate DAPIC to further enhance patient care.”
On April 7, 2025, Metropolis Healthcare share price opened at ₹1,315.00, down from its previous close of ₹1,550.60. At 11:25 AM, the share price of Metropolis Healthcare was trading at ₹1,487.55, down by 4.07% on the NSE.
The acquisition is aligned with Metropolis’ strategic goal of expanding its high-quality diagnostic services across India’s Tier-II cities and beyond.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: Apr 7, 2025, 11:29 AM IST
Nikitha Devi
Nikitha is a content creator with 6+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.
Know MoreWe're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
